Table II.
Seminal exosome-derived miRNAs differentially expressed in OA and/or SA compared with Nz individuals.
| Seminal plasma exosomal miRNA expression | ||||||
|---|---|---|---|---|---|---|
| miRNA | Location | Nz | OA | SA | Deduced miRNA origin from our work | Human miRNA expression profile in tissues |
| A. Underexpressed miRNAs | ||||||
| hsa-miR-202-3p | chr. 10 | 1 | 0.001** | 0.001** | Testis | T (Hu et al., 2014) |
| hsa-miR-514a-3p2cX | chr. X | 1 | 0.001** | 0.001** | Testis | T (Hu et al., 2014) |
| hsa-miR-202-5p | chr. 10 | 1 | 0.004** | 0.004** | Testis | T (Hu et al., 2014); Sertoli cell expressed |
| hsa-miR-509-3-5p1cX | chr. X | 1 | 0.004** | 0.016* | Testis | T (Hu et al., 2014) |
| hsa-miR-510-5p2cX | chr. X | 1 | 0.008** | 0.008** | Testis | |
| hsa-miR-513c-5p3cX | chr. X | 1 | 0.010** | 0.009** | Testis | |
| hsa-miR-518e-3p1c19 | chr. 19 | 1 | 0.029** | 0.080* | Testis | |
| hsa-miR-508-5p1cX | chr. X | 1 | 0.032** | 0.031** | Testis | |
| hsa-miR-520h2c19 | chr. 19 | 1 | 0.036** | 0.054* | Testis | |
| hsa-miR-9-3p | chr. 1, 5, 15 | 1 | 0.049** | 0.047* | Testis | |
| hsa-miR-506-3p1cX | chr. X | 1 | 0.050** | 0.047** | Testis | |
| hsa-miR-383-5p | chr. 8 | 1 | 0.059** | 0.057** | Testis | |
| hsa-miR-34c-5p | chr. 11 | 1 | 0.059** | 0.073* | Testis | T/EP (Hu et al., 2014) |
| hsa-miR-517c-3p2c19 | chr. 19 | 1 | 0.069** | 0.091* | Testis | |
| hsa-miR-873-5p | chr. 9 | 1 | 0.082** | 0.079** | Testis | |
| hsa-miR-34b-5p | chr. 11 | 1 | 0.007* | 0.167* | Testis | |
| hsa-miR-513a-3p1cX | chr. X | 1 | 0.036* | 0.034* | Testis | |
| hsa-miR-5211c19.2c19 | chr. 19 | 1 | 0.042* | 0.040* | Testis | |
| hsa-miR-452-5p | chr. X | 1 | 0.063* | 0.148* | Testis | |
| hsa-miR-122-5p | chr. 18 | 1 | 0.094* | 0.133* | Testis | |
| hsa-miR-449a | chr. 5 | 1 | 0.237* | 0.205** | Testis | |
| hsa-miR-499a-5p | chr. 20 | 1 | 0.343* | 0.315* | Testis | |
| hsa-miR-455-5p | chr. 9 | 1 | 0.382* | 0.297* | Testis | |
| hsa-miR-891b6cX | chr. X | 1 | 0.084* | 0.455 | Epididymis/Testis | EP (Li et al., 2010, 2012; Hu et al., 2014) |
| hsa-miR-8906cX | chr. X | 1 | 0.090* | 0.363 | Epididymis/Testis | EP (Li et al., 2010; Hu et al., 2014) |
| hsa-miR-34c-3p | chr. 11 | 1 | 0.093* | 0.382 | Epididymis/Testis | |
| hsa-miR-891a-5p | chr. X | 1 | 0.097* | 0.448 | Epididymis/Testis | EP (Li et al., 2010, 2012; Hu et al., 2014) |
| hsa-miR-888-5p6cX | chr. X | 1 | 0.098* | 0.391 | Epididymis/Testis | EP (Li et al., 2010; Hu et al., 2014) |
| hsa-miR-124-3p | chr. 8, 20 | 1 | 0.101** | 0.481 | Epididymis/Testis | |
| hsa-miR-892a6cX | chr. X | 1 | 0.107* | 0.544 | Epididymis/Testis | EP (Li et al., 2010; Hu et al., 2014) |
| hsa-miR-551b-3p | chr. 3 | 1 | 0.139** | 0.246 | Epididymis/Testis | |
| hsa-miR-424-5p | chr. X | 1 | 0.212* | 0.424 | Epididymis/Testis | T/EP (Hu et al., 2014) |
| hsa-miR-181b-5p | chr. 1, 9 | 1 | 0.246* | 0.362 | Epididymis/Testis | |
| hsa-miR-31-3p | chr. 9 | 1 | 0.250* | 0.367 | Epididymis/Testis | |
| hsa-miR-181a-5p | chr. 1, 9 | 1 | 0.292* | 0.459 | Epididymis/Testis | |
| hsa-miR-31-5p | chr. 9 | 1 | 0.302* | 0.548 | Epididymis/Testis | T/EP (Hu et al., 2014) |
| hsa-miR-10b-3p | chr. 2 | 1 | 0.313* | 0.923 | Epididymis/Testis | EP (Li et al., 2012) |
| hsa-miR-222-3p | chr. X | 1 | 0.323* | 0.570 | Epididymis/Testis | Wide expression (Hu et al., 2014) |
| hsa-miR-455-3p | chr. 9 | 1 | 0.364* | 0.439 | Epididymis/Testis | |
| hsa-miR-205-5p | chr. 1 | 1 | 0.367* | 0.734 | Epididymis/Testis | |
| hsa-miR-182-3p | chr. 7 | 1 | 0.399* | 1.454 | Epididymis/Testis | EP (Li et al., 2012) |
| hsa-miR-95-3p | chr. 4 | 1 | 0.678* | 1.398 | Epididymis/Testis | |
| hsa-miR-9-5p | chr. 1, 5, 15 | 1 | 0.342 | 0.328* | ||
| hsa-miR-132-5p | chr. 17 | 1 | 0.674 | 0.456* | ||
| hsa-miR-203a | chr. 14 | 1 | 0.995 | 0.880* | ||
| B. Overexpressed miRNAs | ||||||
| hsa-miR-363-3p5cX | chr. X | 1 | 1.474** | 1.241** | ||
| hsa-miR-365a-3p | chr. 16 | 1 | 1.689* | 1.394* | ||
| hsa-miR-29a-3p | chr. 7 | 1 | 1.614* | 1.288 | ||
| hsa-miR-296-5p | chr. 20 | 1 | 3.705* | 2.400 | ||
| hsa-miR-23b-5p | chr. 9 | 1 | 2.590* | 1.498 | ||
| hsa-miR-21-3p | chr. 17 | 1 | 2.202* | 1.485 | ||
| hsa-miR-193a-3p | chr. 17 | 1 | 2.879* | 1.783 | ||
| hsa-miR-29c-3p | chr. 1 | 1 | 1.687* | 1.415 | T/EP (Hu et al., 2014) | |
| hsa-miR-361-3p | chr. X | 1 | 1.741* | 1.575 | ||
| hsa-miR-550a-5p | chr. 7 | 1 | 2.465 | 9.455* | ||
| hsa-miR-423-5p | chr. 17 | 1 | 1.129 | 1.485* | T (Hu et al., 2014) | |
| hsa-let-7f-1-3p | chr. 9 | 1 | 1.093 | 1.808* | ||
| hsa-miR-153-3p | chr. 2, 7 | 1 | 1.667 | 2.251* | ||
| hsa-miR-196b-3p | chr. 7 | 1 | 1.123 | 1.451* | ||
| hsa-miR-96-5p | chr. 7 | 1 | 1.750 | 1.694* | ||
Statistically increased miRNA expression levels are depicted in green; statistically decreased miRNA expression levels are depicted in red
when compared with controls. Hsa, Homo sapiens.
*P < 0.05; ** P < 0.005.
1-6cX clusters in chromosome X.
1-2c19 clusters in chromosome 19.
T, preferential expression in the testis.
EP, preferentially expressed in epididymis.